Literature DB >> 27669828

Weight change trends and overall survival in United States veterans with follicular lymphoma treated with chemotherapy.

Daphne Y Xiao1,2, Suhong Luo1,3, Katiuscia O'Brian1,3, Weijian Liu1, Kenneth R Carson1,3,4.   

Abstract

Understanding weight change patterns in follicular lymphoma (FL) may be important for the assessment of prognosis as well as the long-term care of survivors. A retrospective cohort of United States veterans with a new diagnosis of FL between October 1, 1998 and September 30, 2010 was assembled. Weight changes were evaluated before, during, and after treatment in 896 FL patients who received cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without rituximab (CHOP ± R); cyclophosphamide, vincristine, and prednisone, with or without rituximab (CVP ± R); or rituximab monotherapy. Weight decreased an average of 1.4 kg during therapy, and >5% weight loss during this time period was associated with worse overall survival. Weight increased to an average of 1.4 kg above baseline by 24 months after treatment initiation, with 15% gaining greater than 10% of their baseline weight. Weight management strategies may be an important part of long-term survivorship planning.

Entities:  

Keywords:  Body weight changes; lymphoma; veterans

Mesh:

Substances:

Year:  2016        PMID: 27669828      PMCID: PMC5428550          DOI: 10.1080/10428194.2016.1217526

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  27 in total

1.  Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.

Authors:  L M Hess; R Barakat; C Tian; R F Ozols; D S Alberts
Journal:  Gynecol Oncol       Date:  2007-08-06       Impact factor: 5.482

2.  Obesity in adult lymphoma survivors.

Authors:  Filipa Lynce; Marieta Pehlivanova; Joseph Catlett; Vera Malkovska
Journal:  Leuk Lymphoma       Date:  2011-10-24

3.  The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome.

Authors:  Christian Buske; Eva Hoster; Martin Dreyling; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann
Journal:  Blood       Date:  2006-05-11       Impact factor: 22.113

4.  Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph).

Authors:  Lindsay M Morton; Jennifer J Turner; James R Cerhan; Martha S Linet; Patrick A Treseler; Christina A Clarke; Andrew Jack; Wendy Cozen; Marc Maynadié; John J Spinelli; Adele Seniori Costantini; Thomas Rüdiger; Aldo Scarpa; Tongzhang Zheng; Dennis D Weisenburger
Journal:  Blood       Date:  2007-03-27       Impact factor: 22.113

5.  Improved survival of follicular lymphoma patients in the United States.

Authors:  Wade T Swenson; James E Wooldridge; Charles F Lynch; Valerie L Forman-Hoffman; Elizabeth Chrischilles; Brian K Link
Journal:  J Clin Oncol       Date:  2005-06-27       Impact factor: 44.544

Review 6.  Quality of life and obesity.

Authors:  R L Kolotkin; K Meter; G R Williams
Journal:  Obes Rev       Date:  2001-11       Impact factor: 9.213

7.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

8.  Follicular lymphoma international prognostic index.

Authors:  Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

9.  Impact of weight change during the course of concurrent chemoradiation therapy on outcomes in stage IIIB non-small cell lung cancer patients: retrospective analysis of 425 patients.

Authors:  Erkan Topkan; Cem Parlak; Ugur Selek
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-09-10       Impact factor: 7.038

10.  Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse.

Authors:  Emilie Thivat; Sophie Thérondel; Olivier Lapirot; Catherine Abrial; Pierre Gimbergues; Emilie Gadéa; Eloïse Planchat; Fabrice Kwiatkowski; Marie A Mouret-Reynier; Philippe Chollet; Xavier Durando
Journal:  BMC Cancer       Date:  2010-11-25       Impact factor: 4.430

View more
  2 in total

1.  Deriving Weight From Big Data: Comparison of Body Weight Measurement-Cleaning Algorithms.

Authors:  Richard Evans; Jennifer Burns; Laura Damschroder; Ann Annis; Michelle B Freitag; Susan Raffa; Wyndy Wiitala
Journal:  JMIR Med Inform       Date:  2022-03-09

2.  Comprehensive Characterization of Cachexia-Inducing Factors in Diffuse Large B-Cell Lymphoma Reveals a Molecular Subtype and a Prognosis-Related Signature.

Authors:  Zhixing Kuang; Xun Li; Rongqiang Liu; Shaoxing Chen; Jiannan Tu
Journal:  Front Cell Dev Biol       Date:  2021-05-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.